A Phase I, Double-Blinded, Randomized Controlled Study to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-59 Years in Indonesia
Outcome
To evaluate the safety and immunogenicity of the Lipovaxin Tuberculosis Vaccine in healthy adult populations in Indonesia
Sponsor
PT BIO FARMA (PERSERO)
Date
Upcoming
Subjects
60 subjects